Switch to:
More From Other Websites
Call Martin Shkreli Whatever You Want, But Not A Pharma CEO Feb 05 2016
Op-ed: On IEX, let the market decide Feb 05 2016
String of Q4 Earnings Beat Fails to Revive Pharma ETFs Feb 05 2016
Pfizer's Pipeline Productivity Is Improving Feb 05 2016
It’s Time to Buy This Biotech Gem Feb 04 2016
Merrill Lynch Has 4 Very Oversold Blue Chip Dividend Stocks to Buy Now Feb 04 2016
Pfizer Inc. Earnings Analysis: 2015 By the Numbers Feb 04 2016
Finding Value Inside Opportunity - Analyst Notes on Pfizer, Lowe's Companies, Starbucks and Boeing Feb 04 2016
AstraZeneca doubles profits, warns of lower drug sales Feb 04 2016
Food incubator Brooklyn FoodWorks opens in former Pfizer plant Feb 03 2016
Here's Chardan's 'Conviction Sell' On Axovant Feb 03 2016
Merck gives cautious 2016 outlook as sales of top medicines lag Feb 03 2016
Biotech Stock Roundup: Biogen, Amgen Top Estimates; Zika Virus Grabs Attention Feb 03 2016
Pfizer, J&J, Merck evaluating technologies for Zika vaccine Feb 03 2016
AstraZeneca says new lung cancer pill Tagrisso approved by EU Feb 03 2016
Gilead Q4 Earnings Beat Estimates; Guidance In Line With Street Feb 02 2016
Stocks End Sharply Lower as Oil Falls Feb 02 2016
Business Highlights Feb 02 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

Daniel Seens
ReplyDaniel Seens - 1 year ago
PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership